Enliven Therapeutics (NASDAQ:ELVN) Shares Down 8% – Time to Sell?

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) dropped 8% during mid-day trading on Monday . The company traded as low as $24.50 and last traded at $23.9150. Approximately 71,215 shares traded hands during trading, a decline of 97% from the average daily volume of 2,503,471 shares. The stock had previously closed at $26.00.

Analyst Ratings Changes

ELVN has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Enliven Therapeutics Trading Down 3.7%

The business’s 50-day simple moving average is $19.07 and its two-hundred day simple moving average is $19.95. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -13.60 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $21.82, for a total value of $272,750.00. Following the transaction, the chief executive officer directly owned 890,392 shares of the company’s stock, valued at approximately $19,428,353.44. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anish Patel sold 6,663 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $21.02, for a total transaction of $140,056.26. Following the transaction, the chief operating officer owned 263,311 shares in the company, valued at $5,534,797.22. The trade was a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 68,330 shares of company stock worth $1,434,762. 25.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its position in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares in the last quarter. Quantbot Technologies LP boosted its holdings in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of Enliven Therapeutics in the 3rd quarter worth $96,000. Tower Research Capital LLC TRC raised its holdings in shares of Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after purchasing an additional 3,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS lifted its position in shares of Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after purchasing an additional 2,500 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.